Improve data management workflows with ten genius Excel techniques. Quickly format large numbers in millions without altering ...

Scribe Therapeutics has overshot its own expectations with an IPO that's set to bring in $128.7 million for the in vivo gene editing outfit. Scribe is issuing 8.6 million shares—above the 7.1 million ...

Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing. The Bay Area biotech already disclosed earlier this ...

For many people, managing a disease means chronic therapy. Scribe Therapeutics has a different vision: genetic medicines that offer durable effects for the masses. With its lead program on a path to ...

This article first appeared on GuruFocus. Scribe Therapeutics (NASDAQ:SCTX), a clinical-stage developer of gene therapies for heart disease, surged 67% on Friday after raising $128.7 million in an ...

Scribe Therapeutics Inc. (SCTX) has filed to raise drug development investment in an IPO, according to an S-1 registration statement. The firm is a clinical-stage biopharma developing gene editing ...

Excel Off The Grid explores a lesser-known yet highly effective method for streamlining formula entry in Excel: using AutoCorrect to create short codes for commonly used formula segments. This ...

This article first appeared on GuruFocus. Scribe Therapeutics, a clinical-stage developer of gene therapies for heart disease, is seeking to raise as much as $107.2 million through a U.S. initial ...

Shares of Scribe Therapeutics, a genetic-medicines company co-founded by Nobel laureate Jennifer Doudna, shot up on their first day of trading Friday, continuing a rebound for biotech IPOs this year.

Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, is seeking to raise as much as $107.2 million in a US initial public offering. The Alameda, California-based ...

Scribe Therapeutics (Nasdaq: SCTX) visits the Nasdaq MarketSite in Times Square. Scribe is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to ...

Shares of Scribe Therapeutics are set to make their trading debut Friday after the clinical-stage biotechnology company's upsized initial public offering was priced at the top of expectations, raising ...